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Cannabis use and risk of psychotic or aff ective mental health 
outcomes: a systematic review
Theresa H M Moore, Stanley Zammit, Anne Lingford-Hughes, Thomas R E Barnes, Peter B Jones, Margaret Burke, Glyn Lewis
Summary
Background Whether cannabis can cause psychotic or aff ective symptoms that persist beyond transient intoxication is 
unclear. We systematically reviewed the evidence pertaining to cannabis use and occurrence of psychotic or aff ective 
mental health outcomes.
Methods We searched Medline, Embase, CINAHL, PsycINFO, ISI Web of Knowledge, ISI Proceedings, ZETOC, 
BIOSIS, LILACS, and MEDCARIB from their inception to September, 2006, searched reference lists of studies selected 
for inclusion, and contacted experts. Studies were included if longitudinal and population based. 35 studies from 
4804 references were included. Data extraction and quality assessment were done independently and in duplicate.
Findings There was an increased risk of any psychotic outcome in individuals who had ever used cannabis (pooled 
adjusted odds ratio=1·41, 95% CI 1·20–1·65). Findings were consistent with a dose-response eff ect, with greater risk in 
people who used cannabis most frequently (2·09, 1·54–2·84). Results of analyses restricted to studies of more clinically 
relevant psychotic disorders were similar. Depression, suicidal thoughts, and anxiety outcomes were examined separately. 
Findings for these outcomes were less consistent, and fewer attempts were made to address non-causal explanations, 
than for psychosis. A substantial confounding eff ect was present for both psychotic and aff ective outcomes.
Interpretation The evidence is consistent with the view that cannabis increases risk of psychotic outcomes 
independently of confounding and transient intoxication eff ects, although evidence for aff ective outcomes is less 
strong. The uncertainty about whether cannabis causes psychosis is unlikely to be resolved by further longitudinal 
studies such as those reviewed here. However, we conclude that there is now suffi  cient evidence to warn young people 
that using cannabis could increase their risk of developing a psychotic illness later in life.
Introduction
Cannabis, or marijuana, is the most commonly used 
illegal substance in most countries, including the UK 
and USA.1–3 About 20% of young people now report use 
at least once per week or heavy use (use on >100 occa-
sions).4,5 Use has increased particularly during early ado-
lescence, when the developing brain might be especially 
susceptible to environmental exposures.6 Experi men-
tal studies7–10 and surveys of users11–13 provide strong 
evidence that cannabis intoxication can produce transient, 
and usually mild, psychotic and aff ective exper iences. Of 
greater concern are chronic symptoms that persist 
beyond, or occur independently of, intoxi cation eff ects.
Whether cannabis increases the incidence of estab-
lished syndromes such as schizophrenia or depression is 
unclear, but this question is important because these 
disorders lead to substantial distress for individuals and 
their families, and to public burden from health-care 
costs. Randomised controlled trials (RCTs) of cannabis 
for medical use14 are unlikely to be helpful in addressing 
the question of causality because there are substantial 
diff erences between the pharmacokinetic profi les of such 
preparations and of cannabis used as a recreational drug. 
The typically short follow-up periods of such trials also 
substantially hinder interpretation of results. 
Previous reviews in this fi eld have not been very 
systematic, have examined broad psychosocial outcomes 
rather than mental illness, or have included cross-sectional 
data.15–19 We have systematically reviewed longitudinal 
studies of cannabis use and subsequent psychotic or 
aff ective mental health outcomes, and we have assessed 
the strength of evidence that cannabis use and these 
outcomes are causally related.
Methods
Study selection and data collection 
Studies were included if they were population-based 
longitudinal studies, or case-control studies nested 
within longitudinal designs. We excluded cohorts of 
people with mental illness or substance-use-related 
problems, studies of prison populations, and RCTs of 
cannabis for medical use.14
Diagnostic outcomes for psychosis included 
schizophrenia, schizophreniform, schizoaff ective, or 
psychotic disorders, non-aff ective or aff ective psychoses, 
psychosis not otherwise specifi ed, psychotic symptoms, 
delusions, hallucinations, or thought disorder. Presence 
of delusions, hallucinations, or thought disorder was a 
requirement for all psychosis outcomes. Aff ective, mood, 
or bipolar disorder, aff ective disorder not otherwise 
specifi ed, depression, suicidal ideation or suicide 
attempts, anxiety, neurosis, and mania were included for 
aff ective outcomes.
We searched the following databases from their 
inception to Sept 5, 2006: Medline, Embase, and the 
Cumulative Index to Nursing and Allied Health Literature 
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(CINAHL) on OVID; PsycINFO on WebSPIRS; ISI Web 
of Knowledge and ISI Proceedings; ZETOC (a British 
library database of journal and conference contents); 
BIOSIS on EDINA; and Latin American and Caribbean 
Health Sciences (LILACS) and Caribbean Health Sciences 
Literature (MEDCARIB). We searched using the format 
“([psychosis or schizophrenia or synonyms] or [aff ective 
disorder or depression or synonyms]) and (cannabis or 
synonyms)”, using text words and indexing (MeSH) 
terms (full details are available on GL’s departmental 
website).
The search was restricted to studies on human beings 
but was not limited by language or study design. We 
searched reference lists of included studies, and wrote to 
experts in the fi eld and researchers responsible for 
studies to fi nd other published and unpublished studies 
of relevance. We examined all titles and abstracts, and 
obtained full texts of potentially relevant papers. Working 
independently and in duplicate, we read the papers and 
determined whether they met inclusion criteria using 
eligibility record forms (available on the corresponding 
author’s departmental website). We resolved disagree-
ments by consensus, and extracted data independently 
and in duplicate.
We assessed study quality by recording how potential 
non-causal explanations, particularly bias and confound-
ing factors, were accounted for in each study. We assessed 
information on sampling strategy, response rates, missing 
data, attrition, and attempts to address reverse causation, 
intoxication eff ects, and confounding factors.
Data synthesis
Where study characteristics were judged reasonably 
homogeneous, we grouped studies together and pooled 
data in a meta-analysis; otherwise, we present a narrative 
synthesis of data. We pooled studies using the 
DerSimonian and Laird random-eff ects model20 and the 
metan command in Stata (9·0). Where studies presented 
data only in subgroups, these were incorporated as 
separate studies. We assessed heterogeneity using the I² 
statistic.21 Presence of publication bias was investigated 
by use of funnel plots and Egger’s Test.22 A summary of 
compliance with MOOSE guidelines23 is available on GL’s 
departmental website. 
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had fi nal 
responsibility for the decision to submit for publication. 
Results
Searches of electronic bibliographic databases, expert 
advice, and searches of reference lists of included studies 
and other reviews yielded 4804 references. On the basis 
of their titles and abstracts, we judged that 175 (3·6%) of 
these references potentially contained enough detail to 
be relevant. 143 of these references were excluded as not 
relevant when we had read the whole paper. Details of 
the studies that were excluded at this stage, including 
those that we regarded as near misses, are available on 
GL’s departmental website.
We found 11 studies of psychosis; these reports 
presented data from seven cohort studies. There were 
fi ve adult population-based cohorts: the Epidemiological 
Catchment Area (ECA) study based in the USA;24 the 
Early Developmental Stages of Psychopathology (EDSP) 
study based in Germany;25 the Netherlands Mental Health 
Survey and Incidence Study (NEMESIS);26 the National 
Psychiatric Morbidity Survey (NPMS) based in the UK;27 
and the 1969 Swedish Conscript Cohort.28–30 There were 
also two birth cohorts, from Dunedin31,32 and Christchurch 
(CHDS)33,34 in New Zealand. For the Swedish conscripts 
and CHDS cohorts, data from the most recent reports29,34 
were included in each case because these had longer 
follow-up to cover more events, and had more 
comprehensive analyses to keep reverse causation and 
confounding eff ects to a minimum. Omission of 
individuals with schizophrenia simplex made no 
diff erence to results for schizophrenia in the study of 
Swedish conscripts (Zammit S, unpublished). However, 
results for non-schizophrenia psychoses from this cohort 
were not included because the diagnostic codes that were 
used potentially included many people without psychosis 
as defi ned in this study.
Three of the eligible studies examined psychotic 
disorders, which were defi ned as the presence of 
psychotic symptoms with concurrent evidence of 
impaired functioning (Dunedin,31 NEMESIS,26 and 
Swedish conscripts29), and six studies used the broader 
outcome of psychotic symptoms with no requirement for 
impaired functioning (CHDS,34 Dunedin,31 ECA,24 EDSP,25 
NEMESIS,26 and NPMS27).
For aff ective outcomes, 24 reports were identifi ed from 
15 cohort studies: two birth cohorts from New Zealand 
(CHDS35–37 and Dunedin31,32,38); six adult population-based 




 Odds ratio Reduced risk
 0·01  0·10  0·25  0·50  2  4  10
 Study (symptom of psychosis) Odds ratio (95% CI)
 CHDS (any)*   1·28 (1·04–1·57)
 Dunedin (schizophreniform)*   2·91 (1·20–7·04)
 ECA (any)   1·30 (0·98–1·73)
 EDSP (any)   1·67 (1·13–2·46)
 NEMESIS (any)   2·11 (0·78–5·71)
 NPMS (any)   0·72 (0·30–1·74)
 Swedish (schizophrenia)†   1·50 (1·11–2·02)
 Overall   1·41 (1·20–1·65)
 Increased risk
Figure 1: Forest plot showing adjusted odds ratios and 95% CI for any psychosis outcome according to ever 
use of cannabis in individual studies
Exposure was ever use of cannabis in all studies except for the NPMS, in which the measure was ever use over the 
past 1 year only. *Additional data were provided by investigators in these studies.31,34 †Results were unaltered when 
the 4% of cases with simplex schizophrenia were omitted. 
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cohorts, from the USA (Berkely,39 ECA,40,41 and NY 
state42,43), the UK (NPMS [Haynes J, University of Bristol, 
personal communication]), Australia (Northern Rivers 
Mental Health Study, NoRMHS44), and Colombia;45 and 
seven school-based cohorts, from Australia (Victoria46) 
and the USA (AddHealth,47,48 Baltimore,49 Chicago,50 LA 
schools,51,52 LAT,53 and NY schools54,55). Various outcomes 
were examined, including depression (ten studies), 
depressive symptoms (six studies), suicidal ideation or 
suicide attempts (six studies), anxiety disorders (fi ve 
studies), and anxiety symptoms (one study). We identifi ed 
one study that had data on mania, though there was only 
one event in the whole sample.44
Results for the seven studies included for psychosis are 
summarised in webtable 1 and fi gure 1. There was no evi-
dence to support the presence of publication bias (Egger 
test, p=0·48). The unadjusted results of all studies reported 
evidence of an increased risk of psychosis in people who 
used cannabis compared with non-users. These associa-
tions were reduced, but nevertheless persisted, in six of the 
studies after adjustment for confounding factors.
Estimates were pooled under the assumption that 
measures of psychosis were on a continuum of symptoms 
from mild (self-report of psychotic symptoms) to severe 
(clinical diagnosis of schizophrenia). There was an 
increased risk of a psychotic outcome in individuals who 
ever used cannabis (adjusted odds ratio=1·41, 95% CI 
1·20–1·65; heterogeneity p=0·28; I²=19·2%).
Of the six studies that either examined a linear trend 
across cannabis use frequencies25,26,29,34 or compared 
higher with lower frequency categories,24,27 all reported 
fi ndings that were consistent with a dose-response eff ect. 
Figure 2 shows the associations reported for people with 
most frequent cannabis use compared with non-users of 
cannabis in each study where such data were available. 
In the pooled analysis, there was an increased risk of a 
psychotic outcome in individuals who used cannabis 
most frequently (adjusted odds ratio=2·09, 1·54–2·84; 
heterogeneity p=0·11; I²=44·1%).
We also examined the specifi c relation between 
cannabis use and risk of developing a psychotic disorder. 
The narrowest defi nition of psychotic disorder was in 
the Swedish conscripts study,29 which reported an 
increased risk of schizophrenia in individuals who used 
cannabis. Studies of schizophreniform disorder from 
Dunedin31 (additional data unstratifi ed by age at fi rst use 
were supplied by the researchers) and needs-based 
diagnosis of psychotic disorder from NEMESIS26 also 
showed associations with cannabis use. Pooled data 
from these studies show an increased risk of psychotic 
disorders in individuals who had ever used cannabis 
(adjusted odds ratio=2·58, 1·08–6·13; heterogeneity 
p=0·049; I²=66·9%).
We repeated the pooled analyses for most frequent 
cannabis use and for psychotic disorders but omitted the 
results from NEMESIS because this had the greatest 
eff ect on heterogeneity. In these sensitivity analyses, 
there remained an increased risk of a psychotic outcome 
in people who used cannabis most frequently (odds 
ratio=1·92, 1·50–2·47; heterogeneity p=0·26; I²=25·0%), 
and also an increased risk of psychotic disorders in 
people who had ever used cannabis (odds ratio=1·82, 
1·01–3·30; heterogeneity p=0·16; I²=48·3%).
Two studies have examined diff erential eff ects of 
cannabis on psychosis according to age of fi rst use of this 
drug. In the Dunedin study, a stronger eff ect of cannabis 
on psychotic symptoms was reported for individuals who 
fi rst used cannabis before, as opposed to after, 16 years of 
age.31 There was much weaker evidence for this age eff ect 
for schizophreniform disorder, although the CIs were 
very wide. In the Swedish conscripts study, there was no 
evidence that the eff ect of cannabis on risk of 
schizophrenia diff ered for people who fi rst used cannabis 
before, as opposed to after, age 16 years.30
Other putative interactions were also reported. A 
further report on the Dunedin cohort32 described a strong 
eff ect of cannabis on risk of schizophreniform disorder 
in people homozygous for the valine allele at Val158Met 
within the catechol-O-methyltransferase (COMT) gene 
(crude odds ratio=10·9, 2·2–54·1), with no apparent 
eff ect in methionine homozygotes (crude odds ratio=1·1, 
0·21–5·4) and an intermediate eff ect in heterozygotes. 
This potential interaction was observed only in people 
who fi rst used cannabis before age 18 years, with no 
evidence of interaction in those who fi rst used it after this 
age.
In the EDSP study, the eff ect of cannabis on psychosis 
outcome was stronger in groups described as psychosis 
prone than in non-prone groups.25 However, 
psychosis-prone individuals already had evidence of 
psychotic features at baseline, and this study was 
therefore not examining diff erences in the eff ects of 
cannabis on psychosis incidence between these groups.
We assessed the quality of the studies included for 
psychosis. Because reverse causation, intoxication eff ects, 
and confounding factors could have led to overestimation 
of the true causal association between cannabis use and 
psychosis, we assessed the degree to which the potential 
eff ect of these was kept to a minimum within each study 
(table 1).
 CHDS (daily)   1·56 (1·20–2·03)
 ECA (daily)   2·00 (1·27–3·16)
 EDSP (daily)*   2·23 (1·30–3·83)
 NEMESIS (weekly)*   6·81 (1·79–25·91)
 NPMS (dependence)*   1·47 (0·55–3·93)
 Swedish (>50 times)   3·10 (1·72–5·58)
 Overall   2·09 (1·54–2·84)
 Study (use) Odds ratio (95% CI)
 Odds ratio Reduced risk
 0·05  0·10  0·25  0·50  2  4  10
 Increased risk
 20
Figure 2: Forest plot showing adjusted odds ratios and 95% CI for any psychosis outcome according to most 
frequent use of cannabis in individual studies
*Results were not adjusted for other drug use.
See Online for webtable 1
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Four studies24,26,27,29 excluded participants who had 
experienced psychosis at baseline. In the Swedish 
conscripts study,29 reverse causation was limited further 
by analysis restricted to patients admitted for 
schizophrenia at least 5 years after conscription; this 
analysis produced similar results to the main analysis. 
Three studies25,31,34 adjusted in the analysis for psychotic 
symptoms at baseline. Although this approach partly 
addresses the problem of reverse causation, it averages 
the association between cannabis and psychosis incidence 
with that between cannabis and symptom chronicity or 
relapse. In CHDS,34 structural equation modelling results 
suggested that cannabis use was signifi cantly associated 
with subsequent increase in risk of psychotic symptoms 
rather than vice versa.
Intoxication eff ects were not specifi cally mentioned in 
reports of the ECA24 and NEMESIS26 studies, but the 
outcome assessment (also used in Dunedin31 and EDSP25) 
instructs the interviewer to exclude psychotic symptoms 
that arise solely from drug use. The questionnaires used 
in CHDS34 and NPMS27 do not allow intoxication to be 
assessed. However, exclusion of intoxication eff ects in 
those who use cannabis every day is likely to be very 
diffi  cult. In the Swedish conscripts study,29 use of WHO 
International Classifi cation of Diseases criteria suggests 
that misclassifi cation of a cannabis-intoxication psychosis 
was unlikely; the same is probably true for the Dunedin 
study,31 in which psychosis was defi ned by the presence 
of symptoms of schizophreniform disorder for longer 
than 1 month.
The studies listed in table 1 adjusted for about 
60 diff erent confounding factors, including other 
substance use, personality traits, sociodemographic 
markers, intellectual ability, and other mental health 
problems. For all studies, fully adjusted estimates were 
attenuated, compared with crude results, by an average 
of about 45% (range 10%–80%). In the CHDS, use of 
fi xed-eff ects regression to adjust further for unmeasured 
non-varying confounding factors made little diff erence to 
results.34 Adjustment for other substance use led to a 
substantial attenuation of eff ect in the ECA study24 and 
NEMESIS,26 whereas in the Swedish conscripts study29 
the strongest confounding factors were IQ score, urban 
upbringing, and other mental health disorders.
Loss to follow-up occurred for between 4%31 and 32%27 
of the cohorts we included for psychosis. No data on 
attrition were available from the Swedish conscript 
study.29 Sensitivity analyses from two of the studies26,34 
suggest that attrition might have had small eff ects on 
results, although reclassifi cation of outcome in NEMESIS 
did not diff erentiate between people with diff erent 
cannabis use at baseline.
Depressive outcomes were examined in 15 cohorts 
(webtable 2). There was no evidence to support the 
presence of publication bias (Egger test, ten studies; 
p=0·13). Of ten studies that examined a diagnosis of 
depression or above-threshold rating scores (fi gure 3), 
Attempt to limit reverse 
causation
Attempt to limit intoxication eff ects Approximate 
change from crude 
to adjusted OR (%)*
CHDS33,34† Adjusted for psychotic 
symptoms at previous 
assessment and used SEM 
to address direction of 
causation
Used SCL-90 to measure outcome. This 
does not allow identifi cation of 
symptoms caused by drug intoxication
65% ↓
Dunedin31† Adjusted for psychotic 
symptoms at age 11 years 
(cannabis measures at age 
15 and 18 years)
Used DIS to measure outcome. 
Excluded symptoms caused solely by 
drug use
10% ↓
ECA24 Excluded people with 
psychotic diagnosis at 
baseline
Used DIS to measure outcome. 
Excluded symptoms caused solely by 
drug use 
30% ↓
EDSP25 Adjusted for predisposition 
to psychosis measured at 
baseline
Used M-CIDI to measure outcome. 
Stated that no symptoms were due to 
acute eff ects of drug use
15% ↓
NEMESIS26 Excluded people with 
psychotic symptoms at 
baseline
Used CIDI to measure outcome. Excluded 
symptoms caused by drug use
50% ↓
NPMS27 Excluded people with 
psychotic symptoms at 
baseline
Used PSQ to measure outcome. This 
does not allow identifi cation of 





Excluded people with 
psychotic diagnosis at 
baseline
Used ICD clinical diagnosis of 
schizophrenia as outcome, suggesting 
intoxication eff ects unlikely
60% ↓
OR=odds ratio. SEM=structural equation modelling. SCL-90=symptom checklist 90. DIS=diagnostic interview 
schedule. M-CIDI=Munich version of CIDI. CIDI=composite international diagnostic interview. PSQ=psychosis screening 
questionnaire. ICD=International classifi cation of diseases. ↓=decrease. *Change between crude OR and that after 
adjustment for confounding factors was calculated as (crude OR–adjusted OR)/(crude OR–1). †Additional data, to allow 
estimation of change between crude and adjusted estimates, kindly provided by the researchers. 
Table 1: Information on possible alternative causes for associations reported between cannabis use and 
psychosis outcomes in seven cohorts
 Odds ratio Reduced risk
 0·05  0·10  0·25  0·50  2  4  10
 Increased risk
 20
 AddHealth   1·56 (0·91–2·67)
 CHDS   1·18 (1·01–1·38)
 Colombia   1·31 (0·95–1·80)
 Dunedin (Cb age <15 years)   0·93 (0·27–3·19)
 Dunedin (Cb age 15–18 years)   1·59 (1·06–2·39)
 ECA   4·00 (1·23–12·99)
 NoRMHS*   1·39 (0·32–6·02)
 NPMS (depression and anxiety)   0·77 (0·38–1·57)
 NY schools*   1·12 (0·87–1·45)
 NY state   1·17 (1·04–1·33)
 Victoria (depression and anxiety)   1·40 (0·96–2·04)
 Study Odds ratio (95% CI)
 1  
Figure 3: Forest plot showing adjusted odds ratios and 95% CI for any depression outcome according to 
cannabis exposure in individual studies
Depression outcome measures: centre for epidemiological studies (CES-D) score >22 (AddHealth); diagnostic and 
statistical manual of mental disorders (DSM; CHDS, Dunedin, and NY state); WHO international classifi cation of 
diseases 10th revision (ICD-10; NoRMHS); DSM symptom lasting ≥2 weeks (ECA); clinical interview 
schedule—revised (CIS-R) score ≥12 (NPMS, Victoria); symptom checklist 90 assessment (SCL-90) upper quartile 
(Colombia); and SCL-90 >median score (NY schools). Subgroup data from the Dunedin study were incorporated as 
separate studies. Exposure to cannabis (Cb): ever use (AddHealth, Dunedin, NPMS); current use (NY schools); use 
less than once per week in the past 6 months (Victoria); use at least once per month (Colombia); frequency of use 
(a linear trend across frequency categories; CHDS, NY state); cannabis misuse disorder (ECA, NoRMHS). The point 
estimates of odds ratios (squares) are not visible for studies in which the variance was very high. *Unadjusted 
results calculated from data in tables in the original studies.44
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fi ve reported evidence of an association with cannabis 
use that persisted after adjustment.31,37,40,43,46 However, in 
two of these,31,46 signifi cant associations were observed 
only in subgroup analyses, and in the Dunedin study31 no 
baseline measures of depression were accounted for. 
Weak evidence for association was reported by two 
further studies,45,48 and an association observed in NPMS 
(Haynes J, personal communication) was eliminated 
after adjustment. In view of the heterogeneity across 
these studies in relation to measures of cannabis 
exposure (which included ever use, frequency of use, and 
cannabis misuse disorder), we did not think a 
meta-analysis of these data would be appropriate. Using 
average values from these studies—of 35% having ever 
used cannabis and 15% having developed depression—
we estimated that a sample with more than 230 events 
would be required for 80% power to detect an odds ratio 
for depression of 1·5 (a larger eff ect than was observed in 
most studies). Thus, about half the studies probably had 
insuffi  cient power to observe an association of this size.
Six studies32,38,51–54 from fi ve cohorts examined 
depressive symptoms on a continuous scale. Evidence 
of association was observed in the Berkeley38 and LA 
schools51,52 cohorts (webtable 2). However, in the 
Berkeley study only crude results were presented, and 
the association was observed in men but not women,39 
whereas in the LA schools cohort an increased risk 
observed in an early part of the study51 was not replicated 
in a later wave.52
Of the studies that examined a linear trend across 
cannabis use frequencies37,41,51,52 or that compared higher 
with lower frequency groups46 (Haynes J, personal 
communication), four reported fi ndings that were 
consistent with a dose-response eff ect on depression 
outcomes (webtable 2). Figure 4 shows the associations 
reported for participants with most frequent cannabis 
use compared with non-users, with some evidence for an 
increased risk of depression in a pooled analysis (adjusted 
odds ratio=1·49, 1·15–1·94; heterogeneity p=0·192; 
I²=29·6%).
Seven studies assessed suicidal ideation or suicide 
attempts. Four of these10,37,47,49 reported an association 
between cannabis use and increased risk in adjusted 
analyses and one50 showed little evidence of an association 
(fi gure 5). A reduced risk of attempts51 but increased risk 
of ideation52 were reported from the LA schools cohort 
(webtable 2). 
Of the seven studies that specifi cally examined anxiety 
outcomes (fi gure 6),35,41,42,44,45,51,52 two reported an association 
with cannabis use that persisted after adjustment for 
confounding factors.42,45 In the ECA study of 
obsessive–compulsive disorder, an association was 
observed in a matched sample, but there was little 
evidence for association in the whole sample when a 
more valid unconditional analytical approach was used.41
Several studies reported putative interactions. In the 
NY state study,43 there was a suggestion that risk of 
depression increased with earlier age of fi rst use of 
cannabis. However, in the Dunedin cohort, there was no 
evidence for a greater risk of depression in people who 
fi rst used cannabis before, as opposed to after, age 
16 years.31
 CHDS (≥weekly)   1·70 (1·03–2·79)
 Colombia   1·31 (0·95–1·80)
 ECA   4·00 (1·23–12·99)
 NoRMHS*   1·39 (0·32–6·02)
 NPMS (dependence)   0·90 (0·22–3·63)
 NY state (heavy†)   1·62 (1·11–2·36)
 Victoria (≥weekly: men)   0·47 (0·17–1·30)
 Victoria (≥weekly: women)   1·90 (1·10–3·29)
 Overall   1·49 (1·15–1·94)
 Study (use) Odds ratio (95% CI)
 Odds ratio Reduced risk
 0·05  0·10  0·25  0·50  2  4  10
 Increased risk
 20 1  
Figure 4: Forest plot showing adjusted odds ratios and 95% CI for depression outcomes according to most 
frequent use of cannabis in individual studies
Depression outcome measures: DSM diagnosis (CHDS, NY state); ICD-10 diagnosis (NoRMHS); DSM symptom 
lasting ≥2 weeks (ECA); CIS-R score ≥12 (NPMS, Victoria); and SCL-90 upper quartile (Colombia). Subgroup data 
from the Victoria study were incorporated as separate studies. *Unadjusted results calculated from data in tables in 
the original study.44 †Results for the heavy use category were calculated from results for linear trend across four 
categories of frequency of cannabis use.
 Baltimore 1·80 (1·02–3·17)
 CHDS 1·43 (1·22–1·67)
 Chicago (men)* 1·21 (0·54–2·71)
 Chicago (women)* 0·64 (0·14–2·88)
 ECA 4·55 (1·37–15·11)
 Study Odds ratio (95% CI)
 Odds ratio Reduced risk
 0·05  0·10  0·25  0·50  2  4  10
 Increased risk
 20 1  
Figure 5: Forest plot showing adjusted odds ratios and 95% CI for suicidal ideation according to cannabis 
exposure in individual studies
Cannabis exposure: ever used before age 16 (Baltimore); used >40 occasions (Chicago); frequency of use (linear 
trend across frequency categories; CHDS); cannabis misuse disorder (ECA). *Unadjusted results; subgroup data 
incorporated as separate studies.
See Online for webtable 2
 CHDS   1·20 (0·51–2·84)
 Colombia   1·48 (1·10–2·00)
 ECA (OCD)   2·90 (1·11–7·57)
 NoRMHS*   0·77 (0·18–3·28)
 NPMS (depression and anxiety)   0·77 (0·38–1·57)
 NY state   1·16 (1·00–1·35)
 Victoria (depression and anxiety)   1·40 (0·96–2·04)
 Study Odds ratio (95% CI)
 Odds ratio Reduced risk
 0·10  0·25  0·50  2  4  10
 Increased risk
 1  
Figure 6: Forest plot showing adjusted odds ratios and 95% CI for anxiety outcomes according to cannabis 
exposure in individual studies
Anxiety outcomes: DSM diagnosis (CHDS, ECA, NY state); ICD-10 diagnosis (NoRMHS); CIS-R score ≥12 (NPMS, 
Victoria); SCL-90 upper quartile (Colombia). Cannabis exposure: use in past year (ECA, NPMS); use less than once 
per week for the past 6 months (Victoria); use at least once per month (Colombia); frequency of use (linear trend 
across frequency categories; CHDS, NY state); cannabis disorder (NoRMHS). OCD=obsessive-compulsive disorder. 
*Unadjusted results calculated from data in tables in the original study.44
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There were single reports of interactions between 
cannabis use and age37 and sex.46 As with the results for 
psychosis, an interaction between cannabis use and 
COMT genotype was observed in the Dunedin cohort for 
depression, but not for anxiety.32
We assessed the quality of  the studies included for 
aff ective outcomes by assessing the degree to which the 
potential eff ects of reverse causation, intoxication eff ects, 
and confounding factors were kept to a minimum within 
each study (table 2). Only four studies40,41,48 (Haynes J, 
personal communication) excluded participants with 
aff ective symptoms at baseline. Ten reports35,37,38,42,43,45,46,49,51,55 
adjusted for the baseline measure of the outcome in the 
analyses but, as discussed earlier, this potentially mixes 
the eff ects of cannabis on incidence of aff ective outcome 
with those on symptom chronicity or relapse. In seven stu
dies,31,39,44,47,50,52,53 there was no exclusion of aff ected 
individuals or adjustment for baseline measures in the 
analyses. Three papers42,43,45 from two cohorts reported that 
adjustment for baseline measures of the outcome had a 
negligible eff ect on results. Attempts to exclude intoxication 
eff ects were not explicitly mentioned in any of the 
24 studies, although the questionnaires and interviews 
used for ten of these studies could have enabled raters to 
exclude symptoms attributed to drug intoxication.
About 50 diff erent confounding factors were reported. 
Most of these were related to family and peer relationships, 
adverse life events, criminality, mental health problems, 
sociodemographic markers, and other substance use. 
Five studies39,44,50,53,54 presented only unadjusted results, 
whereas one55 made no mention of the confounding 
factors adjusted for. 
For six of the eight studies in which both crude and 
adjusted results were presented, adjustment led to 
attenuation of associations with cannabis use, ranging 
from 10% to 100% reduction. Adjustment for a 
comprehensive set of confounding factors in the CHDS 
eliminated reasonably strong associations with 
depression, anxiety, and suicidal ideation,35 although 
associations for depression persisted after adjustment in 
a longer follow-up of this cohort.37 In one study of the 
Dunedin cohort,38 adjustment for a more comprehensive 
set of confounding factors than in a more recent report31 
reduced the association between cannabis use and all 
mental disorders by 90%; however, eff ects specifi cally for 
aff ective outcomes were not presented. In the Baltimore 
study, both an increase in eff ect size for suicidal ideation 
and an attenuation of association with suicide attempts 
were observed following adjustment.49
Attrition from the studies included for aff ective outcomes 
ranged from 4%31 to 70%,51 with a median of 20%; loss to 
follow-up was not reported for two of the studies.39,45 
Cannabis use disorder at baseline was associated with 
increased attrition in NoRMHS, although weighting of 
the analyses to account for this made little diff erence to 
the results.44 Attrition was associated with baseline alcohol 
use and disorganised thinking in the LA schools study,52 
Attempt to limit reverse causation Attempt to limit 
intoxication eff ects*
Approximate 
change from crude 
to adjusted OR (%)†
AddHealth47 Not reported. Assessed, but did not 
exclude or adjust, for baseline suicidal 
behaviour 
Not reported Only adjusted 
results presented
AddHealth48‡ Excluded people with depression at 
baseline (CES-D score above threshold)
Not reported. Used CES-D to 
measure outcome
45% ↓
Baltimore49 Adjusted for childhood depression at 
age 8 years
Not reported. Used NIMH 
interview to measure outcome
40% ↓ to 60% ↑
Berkeley39 Not reported Not reported. Used CES-D to 
measure outcome
Only crude results 
presented
CHDS35 Adjusted for anxiety and depression 
at baseline
Not reported. Used DIS and 
DISC to measure outcome
50–60% ↓
CHDS37 Adjusted for anxiety and depression 
at baseline
Not reported. Used DISC and 
CIDI to measure outcome
25% ↓
Chicago50 Not reported Not reported Only crude results 
presented
Columbia45 Adjusted for distress (anxiety and 
depression) at baseline




Dunedin38 Adjusted for baseline mental disorder Not reported. Used DIS and 
DISC to measure outcome
93% ↓ for all 
mental disorders
Dunedin31 Not reported. Screened, but did not 
exclude or adjust, for depression at 
baseline 




ECA41 Excluded people with history of OCD 
at baseline
Not reported. Used DIS to 
measure outcome
215% ↑
ECA40 Excluded people with lifetime ever 
DSM-III-R symptoms of depression 
>2 weeks 
Not reported. Used DIS and 
symptoms present most days 
for >2 weeks
10% ↓
LA schools51 Adjusted for previous emotional 
distress, including depression
Not reported. Used CES-D and 
HSC to measure outcome
Only adjusted 
results presented




LAT53 Not reported. Assessed, but did not 
exclude or adjust, for baseline 
depressive symptoms
Adjusting for cannabis use at 
outcome made no diff erence 
to results. Used CES-D and 
CIDI to measure outcome
Only crude results 
presented
NoRMHS44 Not reported. Did not exclude or 
adjust for baseline measures
Not reported. Used CIDI to 
measure outcome
Only crude results 
presented
NPMS§ Excluded people with baseline CIS-R 
≥12 Adjusted for CIS-R <12
Not reported. Used CIS-R to 
measure outcome
80–100%↓
NY schools54 Results calculated by us are with 
exclusion of people with baseline 
depressive symptoms
Not reported. Used SCL to 
measure outcome
Only crude results 
presented
NY schools55 Adjusted for depression score at 
baseline




NY state42 Adjusted for previous depression or 
anxiety








Victoria46 Adjusted for previous depression and 
anxiety
Not reported. Used CIS-R to 
measure outcome
Up to 40% ↓
OR=odds ratio. CES-D=centre for epidemiological studies—depression scale. DIS=diagnostic interview schedule. 
DISC=diagnostic interview schedule for children. CIDI=composite international diagnostic interview. SCL-90=symptom 
checklist 90. OCD=obsessive-compulsive disorder. DSM-III-R=diagnostic and statistical manual of mental disorders, third 
edition, revised. CIS-R=clinical interview schedule—revised. HSC=Hopkins symptom checklist. ↓=decrease. ↑=increase. 
*DIS, DISC, and CIDI potentially allow exclusion of intoxication eff ects, although none of the studies states explicitly that 
this was done. CES-D, CIS-R, HSC, and SCL do not allow attempts to exclude intoxication eff ects. †Change between crude 
OR and that after adjustment for confounding factors was calculated as (crude OR–adjusted OR)/(crude OR–1). 
‡Additional data on crude and adjusted estimates were provided by the researchers.§Haynes J, personal communication.
Table 2: Information on possible alternative causes for associations reported between cannabis use and 
aff ective outcomes in 15 cohorts
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but was not associated with baseline substance use in the 
LAT study.53 However, in the ECA study individuals with 
baseline depression and cannabis misuse were both more 
likely to be available for follow-up.40
Discussion
We found a consistent increase in incidence of psychosis 
outcomes in people who had used cannabis. There was no 
statistical evidence of publication bias, although this 
fi nding was based on only seven studies. The pooled 
analysis revealed an increase in risk of psychosis of about 
40% in participants who had ever used cannabis. However, 
studies tended to report larger eff ects for more frequent 
use, with most studies showing a 50–200% increase in risk 
for participants who used most heavily. A dose-response 
eff ect was observed in all studies that examined the relation 
to increasing cannabis exposure. Only three studies26,29,31 
examined psychotic disorders as an outcome; the presence 
of functional impairment makes these studies relevant to 
clinical practice. The results from these studies were also 
consistent with an increased risk in people who used 
cannabis.
Studies included in the pooled analyses used diff erent 
methods to measure cannabis exposure and to assess 
outcome. For example, use of the symptom checklist 
90 assessment in the CHDS34 might have led to inclusion 
of participants without psychotic symptoms as defi ned in 
this review. This heterogeneity was refl ected in the large I² 
values for some of the pooled results. The features of 
NEMESIS26 that caused this study to increase between-study 
heterogeneity to a greater extent than the other studies are 
not clear, but heterogeneity decreased when this study was 
omitted from the sensitivity analyses, even though results 
were largely unchanged. 
Arguments for why earlier use of cannabis might have 
more harmful eff ects are intuitively compelling, but no 
robust evidence supports this view. The increased risk of 
psychosis in people using cannabis from a younger age 
observed in the Dunedin cohort could indicate a greater 
cumulative exposure to cannabis rather than a sensitive 
period of exposure.31 In the Swedish conscripts study, in 
which cumulative use of cannabis was examined, no 
diff erence in risk according to age at fi rst use was 
observed.30 Similarly, evidence for eff ect modifi cation 
between cannabis use and COMT variation on psychosis 
risk is very weak: this eff ect was observed in only a 
subgroup of people within the Dunedin cohort,32 and 
evidence for such an interaction in an experimental setting 
was also observed in only a subgroup of participants.56
Almost all studies reported an increased risk of aff ective 
outcomes in people who used cannabis, although CIs were 
generally consistent with null eff ects. However, eff ect sizes 
were small, and many studies were probably underpowered. 
For example, odds ratios for depression ranged from 
1·3 to 1·6 for the highest exposure categories of weekly or 
monthly cannabis use, with one exception (the ECA study 
of cannabis misuse disorder).40
An association seen in an observational study does not 
necessarily refl ect a causal relation. Because most of the 
studies for psychosis excluded people with psychosis at 
baseline, the observed associations are unlikely to refl ect 
reverse causation. However, the majority of studies for 
aff ective outcomes did not adequately address the 
problem of reverse causation as a possible alternative 
explanation for any association observed. For cannabis 
and psychosis, there was evidence of confounding eff ects, 
but the associations persisted in almost all studies, even 
after adjustment for comprehensive lists of variables, 
including markers of premorbid disturbances that are 
commonly observed in patients with schizophrenia. All 
of the studies that reported an association for psychosis 
adjusted for other drug use, although two of the studies26,31 
made no adjustment for alcohol use. Furthermore, three 
studies25,26,31 for psychosis made no adjustment for other 
mental health disorders at baseline, and measures of 
disorders adjusted for in the other studies24,25,29,34 are 
unlikely to have accurately captured all mental health 
symptoms at baseline given the scope of the assessment 
tools generally used.
Residual confounding by these or other factors can 
never be eliminated from observational studies. 
Adjustment for confounding factors in studies of aff ective 
outcomes seemed to be more important than in studies 
of psychotic outcomes, and in some studies such 
adjustment explained all the observed association. There 
was also more variation for aff ective outcomes than for 
psychosis, with increases in crude estimates reported in 
two studies.41,49 Furthermore, roughly half the studies 
made no adjustment for alcohol or other drug use. 
Confounding factors seem more likely to explain the 
reported association between cannabis and aff ective 
outcomes than that between cannabis and psychosis.
Most studies of psychosis made some attempt to reduce 
the chance that the outcome examined was due directly 
to eff ect of intoxication with cannabis, although this can 
be a diffi  cult judgment in people who use cannabis 
frequently. Misdiagnosis as cannabis intoxication was 
unlikely in the Swedish conscripts study,29 in which the 
outcome was admission to hospital with schizophrenia, 
or in the Dunedin cohort,31 in which the outcome was 
presence of schizophreniform symptoms for longer than 
1 month. The possibilities of intoxication and withdrawal 
eff ects were not considered in any of the studies of 
aff ective outcomes, although both of these can result 
from cannabis consumption.7,57
We would expect both confounding factors and 
intoxication to lead to an increase in the observed 
association. However, underestimation of eff ects could 
also have occurred. Measurement of cannabis use is 
especially diffi  cult because there is almost certainly large 
variation in biologically available cannabinoid concen-
trations, resulting from diff erent sources of cannabis and 
from diff erent intake practices; self-reported frequency of 
use is also prone to error. Such misclassi fi cation, if ran-
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dom, would usually make detection of an association 
more diffi  cult. However, diff erential mis classifi cation 
could lead to overestimates of association. For example, 
stimulant use is more common in people who use 
cannabis than in those who do not, so under-reporting of 
stimulant use might diff erentially aff ect the results from 
cannabis users.
Attrition in cohort studies is more likely in people who 
use drugs and in those who develop mental health 
problems than in other participants,58,59 and this would 
also lead to underestimates of association. Evidence for 
such a pattern of attrition was present in NoRMHS44 and 
the LA schools study.52 In the ECA study,40 participants 
with baseline depression were more likely to remain in 
the study, although pattern of loss in relation to incident 
depression is unknown. The extent to which such bias 
would aff ect the results is unclear, although modelling 
for attrition in CHDS,34 NEMESIS,26 and NoRMHS44 
suggests that bias caused by attrition had little eff ect on 
the overall fi ndings.
Recent estimates of the proportion of adolescents and 
young adults in the UK who have ever used cannabis are 
around 40%.2 If having ever used cannabis increases risk 
of a psychotic outcome by 1·4 times (as suggested from 
the pooled analysis), we can estimate that about 14% 
(95% CI 7–19) of psychotic outcomes in young adults 
currently in the UK would not occur if cannabis were not 
consumed. However, such estimates rely heavily on the 
assumption that the association between cannabis use 
and psychosis is causal, and that the pooled relative risk 
is an accurate estimate of this causal eff ect.
Projected trends for schizophrenia incidence have not 
paralleled trends in cannabis use over time, and this 
apparent mismatch has been used as an argument 
against causal eff ects.60 However, other projections 
suggest that time lags and a lack of reliable incidence 
data might mean that changes in schizophrenia incidence 
are not yet fully apparent.61
Even seemingly robust fi ndings from observational 
studies have sometimes not been confi rmed by RCTs.62 
However, in some situations RCTs are not feasible, and 
reliance must be placed on interpretation of results from 
the best available evidence from observational studies.63 
The neurobiological sequelae of cannabis use, including 
modulated activity of dopaminergic, GABAergic, and 
glutamatergic neurons,64–66 are consistent with abnor mal-
ities described in people with psychotic disorders.67 Further-
more, evidence that cannabis can produce transient 
psychotic and mood-altering symptoms in experi mental 
studies7–10 lends support to a causal explanation for the 
associations between cannabis use and more chronic 
psychotic and aff ective disorders.
We are not aware of any other systematic reviews that 
focus on the relation between cannabis and aff ective 
outcomes. A previous systematic review of cannabis use 
and psychosis included cross-sectional studies and did not 
address study quality.19 Another systematic review 
examined broader psychosocial outcomes,18 but the lack of 
focus specifi cally on psychotic or aff ective disorders meant 
that the explanations for associations could not be 
examined in detail. Previous meta-analyses from both 
systematic19 and narrative15,17 reviews (table 3) have included 
cross-sectional data17,19 or used unadjusted results,19 and 
combined eff ects for ever-use of cannabis with those for 
dependence.15,17,19 As might be expected, all report larger 
eff ects than observed in this study, although direct 
comparison of these eff ects with our fi ndings is diffi  cult.
There are potential problems with meta-analyses of 
observational data.68 However, we applied robust 
methods to identify as many publications as we could, 
and attempted to interpret the fi ndings as appropriately 
as possible by including a thorough critique of individual 





Systematic review of 
cannabis use and 
psychosis
Search strategy specifi ed databases, search terms used, 
and dates of search
Stated criteria for inclusion of studies
Did not assess study quality
Did not provide statement of compliance with MOOSE 
guidelines
Cross-sectional and 
longitudinal studies of 
high-risk groups
Included cross-sectional and longitudinal data
Results from this meta-analysis are not consistent with our results; 
however, use of unadjusted estimates in this meta-analysis, and 
combining eff ects for ever-use of cannabis with those for 
dependence, makes it diffi  cult to compare directly with our fi ndings
Macleod 
et al18
Systematic review of 
cannabis and other illicit 
drugs and psychological 
and social harm
Search strategy specifi ed databases, search terms used, 
and dates
Stated criteria for inclusion of studies
Assessed study quality
Did not provide statement of compliance with MOOSE 
guidelines
Longitudinal studies
Examined several broad 
psychosocial outcomes, 





Narrative review of 
cannabis and psychosis
Search strategy specifi ed databases searched, but not 
search terms used or dates of search
Stated criteria for inclusion of studies
Did not describe methods used to assess study quality
Cross-sectional and 
longitudinal, although 
results were reported 
separately
Meta-analysis was of longitudinal studies only. Included duplication 
of Swedish conscript data and one stratum of subgroup data for the 
Dunedin study. Combination of eff ects for ever-use of cannabis with 
those for dependence makes it diffi  cult to compare with our fi ndings
Henquet 
et al17
Narrative review of 
cannabis and psychosis
Did not describe search strategy
Did not state criteria for inclusion of studies
Did not describe methods used to assess study quality
Cross-sectional and 
longitudinal
Included cross-sectional and longitudinal data 
Combination of eff ects for ever-use of cannabis with those for 
dependence makes it diffi  cult to compare with our fi ndings
Table 3: Summary of previously published systematic reviews or narrative reviews with meta-analyses
Articles
www.thelancet.com   Vol 370   July 28, 2007 327
studies, and by doing a comprehensive assessment of 
alternative explanations for associations reported. 
Even if the methods of future longitudinal studies are 
more robust, these studies are likely to encounter similar 
limitations to those discussed here. However, 
improvement in the measurement of cannabis exposure 
and elimination of intoxication eff ects might reduce 
some of the uncertainty. Animal models of long-term 
eff ects of cannabis on neuropsychological domains 
relevant to psychotic or aff ective states could also improve 
knowledge.69 Further study is needed to establish whether 
cannabis is more harmful in younger age groups, and 
whether risk is modifi ed by genetic or other factors. The 
question of whether cannabis causes psychotic or 
aff ective disorders is perhaps the wrong one to be asking, 
because it will be diffi  cult to answer with any degree of 
certainty. What is more pertinent is whether the evidence 
that is now available can justify policy implications, such 
as public education campaigns to alert people to the 
possible risks associated with cannabis.
In conclusion, we have described a consistent 
association between cannabis use and psychotic 
symptoms, including disabling psychotic disorders. The 
possibility that this association results from confounding 
factors or bias cannot be ruled out, and these uncertainties 
are unlikely to be resolved in the near future. Despite the 
inevitable uncertainty, policymakers need to provide the 
public with advice about this widely used drug. We 
believe that there is now enough evidence to inform 
people that using cannabis could increase their risk of 
developing a psychotic illness later in life. The evidence 
that cannabis use leads to aff ective outcomes is less 
strong than for psychosis but is still of concern. Although 
individual lifetime risk of chronic psychotic disorders 
such as schizophrenia, even in people who use cannabis 
regularly, is likely to be low (less than 3%), cannabis use 
can be expected to have a substantial eff ect on psychotic 
disorders at a population level because exposure to this 
drug is so common.
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